BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23825999)

  • 1. Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis.
    Alavian SM; Tabatabaei SV; Behnava B; Rizzetto M
    J Res Med Sci; 2012 Oct; 17(10):967-74. PubMed ID: 23825999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
    Abdrakhman A; Ashimkhanova A; Almawi WY
    Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alpha-2b therapy in chronic hepatitis delta.
    Keshvari M; Alavian SM; Sharafi H; Karimi G; Gholami Fesharaki M
    Hepat Mon; 2014 Mar; 14(3):e15729. PubMed ID: 24744790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
    Wedemeyer H; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP;
    Lancet Infect Dis; 2019 Mar; 19(3):275-286. PubMed ID: 30833068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha for chronic hepatitis D.
    Abbas Z; Khan MA; Salih M; Jafri W
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD006002. PubMed ID: 22161394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience.
    Bahcecioglu IH; Ispiroglu M; Demirel U; Yalniz M
    Hepat Mon; 2015 Mar; 15(3):e24366. PubMed ID: 25861318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
    Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
    N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
    Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
    J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
    Niro GA; Ciancio A; Gaeta GB; Smedile A; Marrone A; Olivero A; Stanzione M; David E; Brancaccio G; Fontana R; Perri F; Andriulli A; Rizzetto M
    Hepatology; 2006 Sep; 44(3):713-20. PubMed ID: 16941685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.